Free Trial
NASDAQ:LMAT

LeMaitre Vascular (LMAT) Stock Price, News & Analysis

LeMaitre Vascular logo
$102.02 +0.50 (+0.49%)
(As of 11/15/2024 ET)

About LeMaitre Vascular Stock (NASDAQ:LMAT)

Key Stats

Today's Range
$100.45
$102.44
50-Day Range
$85.64
$105.50
52-Week Range
$51.70
$106.49
Volume
80,760 shs
Average Volume
147,954 shs
Market Capitalization
$2.29 billion
P/E Ratio
55.75
Dividend Yield
0.63%
Price Target
$94.57
Consensus Rating
Moderate Buy

Company Overview

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

LeMaitre Vascular Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
73rd Percentile Overall Score

LMAT MarketRank™: 

LeMaitre Vascular scored higher than 73% of companies evaluated by MarketBeat, and ranked 309th out of 971 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LeMaitre Vascular has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LeMaitre Vascular has only been the subject of 4 research reports in the past 90 days.

  • Read more about LeMaitre Vascular's stock forecast and price target.
  • Earnings Growth

    Earnings for LeMaitre Vascular are expected to grow by 11.34% in the coming year, from $1.94 to $2.16 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LeMaitre Vascular is 55.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 121.85.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LeMaitre Vascular is 55.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 101.92.

  • Price to Earnings Growth Ratio

    LeMaitre Vascular has a PEG Ratio of 2.51. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    LeMaitre Vascular has a P/B Ratio of 6.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LeMaitre Vascular's valuation and earnings.
  • Percentage of Shares Shorted

    3.83% of the float of LeMaitre Vascular has been sold short.
  • Short Interest Ratio / Days to Cover

    LeMaitre Vascular has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in LeMaitre Vascular has recently decreased by 32.37%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    LeMaitre Vascular has a dividend yield of 0.63%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    LeMaitre Vascular has been increasing its dividend for 13 years.

  • Dividend Coverage

    The dividend payout ratio of LeMaitre Vascular is 34.97%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 29.63% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.

  • Read more about LeMaitre Vascular's dividend.
  • Percentage of Shares Shorted

    3.83% of the float of LeMaitre Vascular has been sold short.
  • Short Interest Ratio / Days to Cover

    LeMaitre Vascular has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in LeMaitre Vascular has recently decreased by 32.37%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    LeMaitre Vascular has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for LeMaitre Vascular this week, compared to 4 articles on an average week.
  • Search Interest

    Only 1 people have searched for LMAT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added LeMaitre Vascular to their MarketBeat watchlist in the last 30 days. This is an increase of 333% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LeMaitre Vascular insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.79% of the stock of LeMaitre Vascular is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LeMaitre Vascular's insider trading history.
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

LMAT Stock News Headlines

LeMaitre Vascular (NASDAQ:LMAT) Raised to Buy at StockNews.com
The only candlestick pattern worth a darn
It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…
KeyBanc Remains a Hold on Lemaitre Vascular (LMAT)
Lemaitre Vascular (LMAT) Gets a Buy from Stifel Nicolaus
See More Headlines

LMAT Stock Analysis - Frequently Asked Questions

LeMaitre Vascular's stock was trading at $56.76 at the beginning of the year. Since then, LMAT stock has increased by 79.7% and is now trading at $102.02.
View the best growth stocks for 2024 here
.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced its quarterly earnings results on Thursday, October, 31st. The medical instruments supplier reported $0.49 EPS for the quarter, beating analysts' consensus estimates of $0.44 by $0.05. The firm's revenue was up 15.6% on a year-over-year basis.

LeMaitre Vascular subsidiaries include Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and more.

LeMaitre Vascular's top institutional investors include Conestoga Capital Advisors LLC (8.81%), Copeland Capital Management LLC (5.18%), Geneva Capital Management LLC (3.91%) and State Street Corp (3.66%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Trent G Kamke, Bridget A Ross and John A Roush.
View institutional ownership trends
.

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Ex-Dividend for 8/29 Dividend
8/15/2024
Dividend Payable
8/29/2024
Last Earnings
10/31/2024
Today
11/17/2024
Ex-Dividend for 12/5 Dividend
11/21/2024
Dividend Payable
12/05/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/25/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:LMAT
Employees
614
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$94.57
High Stock Price Target
$105.00
Low Stock Price Target
$75.00
Potential Upside/Downside
-7.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$30.10 million
Pretax Margin
25.43%

Debt

Sales & Book Value

Annual Sales
$193.48 million
Cash Flow
$1.79 per share
Book Value
$14.73 per share

Miscellaneous

Free Float
20,058,000
Market Cap
$2.29 billion
Optionable
Optionable
Beta
0.89

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:LMAT) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners